AR037427A1 - Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento - Google Patents
Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimientoInfo
- Publication number
- AR037427A1 AR037427A1 ARP020104526A ARP020104526A AR037427A1 AR 037427 A1 AR037427 A1 AR 037427A1 AR P020104526 A ARP020104526 A AR P020104526A AR P020104526 A ARP020104526 A AR P020104526A AR 037427 A1 AR037427 A1 AR 037427A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- procedure
- quinoline
- compound
- pharmaceutical composition
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 3
- -1 QUINOLINE COMPOUND Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XXXJMHLYVRHRNH-UHFFFAOYSA-N n-hydroxy-n-[1-(oxolan-2-yl)-2-(quinolin-3-ylmethylsulfonyl)ethyl]formamide Chemical compound C=1N=C2C=CC=CC2=CC=1CS(=O)(=O)CC(N(C=O)O)C1CCCO1 XXXJMHLYVRHRNH-UHFFFAOYSA-N 0.000 abstract 1
- 238000012261 overproduction Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de quinolina inhibidor de la formación de sCD23 soluble humano que es N-[2-(3-quinolilmetanosulfonil)-1-tetrahidrofuran-2-iletil]-N-hidroxiformamida de fórmula (1). Uso de dicho compuesto para preparar un medicamento para el tratamiento o profilaxis de trastornos en los que está implicada la sobreproducción de sCD23, y composición farmacéutica que lo comprende junto con, opcionalmente, un vehículo farmacéuticamente aceptable. Procedimiento para preparar dicho compuesto y compuestos de quinolina útiles como intermediarios de síntesis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0128378.7A GB0128378D0 (en) | 2001-11-27 | 2001-11-27 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037427A1 true AR037427A1 (es) | 2004-11-10 |
Family
ID=9926525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104526A AR037427A1 (es) | 2001-11-27 | 2002-11-25 | Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7045626B2 (es) |
| EP (1) | EP1448552B1 (es) |
| JP (1) | JP2005513036A (es) |
| AR (1) | AR037427A1 (es) |
| AT (1) | ATE334124T1 (es) |
| AU (1) | AU2002365511A1 (es) |
| DE (1) | DE60213450T2 (es) |
| ES (1) | ES2268133T3 (es) |
| GB (1) | GB0128378D0 (es) |
| TW (1) | TW200303745A (es) |
| WO (1) | WO2003045938A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080083071A (ko) | 2003-08-08 | 2008-09-12 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
| DK2780015T3 (en) | 2011-11-18 | 2017-03-27 | Heptares Therapeutics Ltd | M1 MUSCARINRECEPTORAGONISTER |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199903287T2 (xx) | 1997-07-31 | 2000-09-21 | Abbott Laboratories | Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri. |
| PL200418B1 (pl) * | 1998-01-30 | 2009-01-30 | Darwin Discovery Ltd | Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie |
-
2001
- 2001-11-27 GB GBGB0128378.7A patent/GB0128378D0/en not_active Ceased
-
2002
- 2002-11-25 US US10/496,193 patent/US7045626B2/en not_active Expired - Fee Related
- 2002-11-25 TW TW091134147A patent/TW200303745A/zh unknown
- 2002-11-25 DE DE60213450T patent/DE60213450T2/de not_active Expired - Lifetime
- 2002-11-25 EP EP02790436A patent/EP1448552B1/en not_active Expired - Lifetime
- 2002-11-25 WO PCT/EP2002/013264 patent/WO2003045938A1/en active IP Right Grant
- 2002-11-25 AU AU2002365511A patent/AU2002365511A1/en not_active Abandoned
- 2002-11-25 ES ES02790436T patent/ES2268133T3/es not_active Expired - Lifetime
- 2002-11-25 AT AT02790436T patent/ATE334124T1/de not_active IP Right Cessation
- 2002-11-25 AR ARP020104526A patent/AR037427A1/es not_active Application Discontinuation
- 2002-11-25 JP JP2003547388A patent/JP2005513036A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1448552A1 (en) | 2004-08-25 |
| ES2268133T3 (es) | 2007-03-16 |
| JP2005513036A (ja) | 2005-05-12 |
| DE60213450D1 (de) | 2006-09-07 |
| GB0128378D0 (en) | 2002-01-16 |
| ATE334124T1 (de) | 2006-08-15 |
| TW200303745A (en) | 2003-09-16 |
| WO2003045938A1 (en) | 2003-06-05 |
| DE60213450T2 (de) | 2007-09-20 |
| EP1448552B1 (en) | 2006-07-26 |
| AU2002365511A1 (en) | 2003-06-10 |
| US20050085505A1 (en) | 2005-04-21 |
| US7045626B2 (en) | 2006-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2325389C2 (ru) | Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью | |
| BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| ECSP034732A (es) | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias | |
| BRPI0409109A (pt) | novos compostos | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| SE0200979D0 (sv) | New compounds | |
| ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
| DE60220887D1 (de) | Agonisten von beta-adrenorezeptoren | |
| EA200500354A1 (ru) | Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) | |
| SE0104340D0 (sv) | New compounds | |
| MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
| SE0100569D0 (sv) | New compounds | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| AR037427A1 (es) | Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento | |
| SE0401655D0 (sv) | New compounds | |
| ES2177671T3 (es) | Benzamida enterocinetica. | |
| BRPI0410623A (pt) | composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto | |
| BRPI0411729A (pt) | dicetopiperazinas substituìdas e seu uso como antagonistas da oxitocina | |
| IT1307786B1 (it) | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |